Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 6/20 | 0.51 |
| ▸ | BRAF | P15056 | 7/20 | 0.46 |
| ▸ | RAF1 | P04049 | 5/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.39 |
| ▸ | TTBK1 | Q5TCY1 | 2/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | BCR | P11274 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4365818 | 0.69 | KDR (0.66) | KDRBRAFRAF1ROCK2MET | |
| SCHEMBL4361243 | 0.68 | KDR (1.00) | KDR | |
| SCHEMBL4364229 | 0.67 | KDR (0.80) | KDRMET | |
| SCHEMBL4814436 | 0.66 | KDR (0.52) | KDRBRAFRAF1MAPK14TNNI3K | |
| SCHEMBL4363875 | 0.66 | MEN1 (0.63) | KDRBRAFRAF1MAPK14TNNI3K | |
| SCHEMBL4362982 | 0.66 | KDR (1.00) | KDRMET | |
| SCHEMBL4816425 | 0.65 | MET (0.49) | KDRBRAFMAPK14TNNI3KROCK2 | |
| SCHEMBL18435808 | 0.65 | BRAF (0.65) | KDRBRAFRAF1MAPK14TNNI3K | |
| SCHEMBL2747222 | 0.64 | KDR (0.57) | KDRBRAFMAPK14TNNI3KMET | |
| SCHEMBL19879433 | 0.63 | BRAF (1.00) | BRAFRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531553-B2 | Heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531553-B2 | Heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531553-B2 | Heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-05-12 | — | — | US | disclosed |
| EP-1638954-A1 | FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS | AMGEN INC. (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20040209892-A1 | Heterocyclic compounds and methods of use | U.S. PATENT OPERATIONS | 2004-10-21 | — | — | US | disclosed |
| WO-2004085425-A1 | FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS | AMGEN INC (US) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209892-A1 | Heterocyclic compounds and methods of use | VHL, NQO1, HPGDS | KDR 83/4885BRAF 612/4885RAF1 1846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.